Literature DB >> 32613271

Characterizing caspase-1 involvement during esophageal disease progression.

Gillian Barber1,2, Akanksha Anand3, James J Phelan2, Aisling B Heeran2, Ewelina Flis1, Niamh E Clarke2, Jenny A Watson4, Julia Strangmann3, Brian Flood1, Hazel O'Neill2, Dermot O'Toole5, Finbar MacCarthy5, Narayanasamy Ravi2,5, John V Reynolds2,5, Elaine W Kay4, Michael Quante3, Jacintha O'Sullivan6, Emma M Creagh7.   

Abstract

Barrett's esophagus (BE) is an inflammatory condition and a neoplastic precursor to esophageal adenocarcinoma (EAC). Inflammasome signaling, which contributes to acute and chronic inflammation, results in caspase-1 activation leading to the secretion of IL-1β and IL-18, and inflammatory cell death (pyroptosis). This study aimed to characterize caspase-1 expression, and its functional importance, during disease progression to BE and EAC. Three models of disease progression (Normal-BE-EAC) were employed to profile caspase-1 expression: (1) a human esophageal cell line model; (2) a murine model of BE; and (3) resected tissue from BE-associated EAC patients. BE patient biopsies and murine BE organoids were cultured ex vivo in the presence of a caspase-1 inhibitor, to determine the importance of caspase-1 for inflammatory cytokine and chemokine secretion.Epithelial caspase-1 expression levels were significantly enhanced in BE (p < 0.01). In contrast, stromal caspase-1 levels correlated with histological inflammation scores during disease progression (p < 0.05). Elevated secretion of IL-1β from BE explanted tissue, compared to adjacent normal tissue (p < 0.01), confirmed enhanced activity of caspase-1 in BE tissue. Caspase-1 inhibition in LPS-stimulated murine BE organoids caused a significant reduction in IL-1β (p < 0.01) and CXCL1 (p < 0.05) secretion, confirming the importance of caspase-1 in the production of cytokines and chemokines associated with disease progression from BE to EAC. Targeting caspase-1 activity in BE patients should therefore be tested as a novel strategy to prevent inflammatory complications associated with disease progression.

Entities:  

Keywords:  Barrett’s metaplasia; Esophageal cancer; Inflammasome; Inflammation

Year:  2020        PMID: 32613271     DOI: 10.1007/s00262-020-02650-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.

Authors:  Di-Guang Wen; Xiao-Ping Zhao; Yu You; Zuo-Jin Liu
Journal:  Cancer Immunol Immunother       Date:  2020-09-28       Impact factor: 6.968

2.  Constructing novel molecular subtypes and an 11-gene signature based on pyroptosis signaling for lung adenocarcinoma.

Authors:  Lu Li; Qing He; Zhenchao Tao; Rui Zhang; Yayun Cui; Liting Qian
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

3.  A Predictive Model Based on Pyroptosis-Related Gene Features Can Effectively Predict Clear Cell Renal Cell Carcinoma Prognosis and May Be an Underlying Target for Immunotherapy.

Authors:  Yufu Wang; Jinhui Liu; Lishuo Zhang; Yifei Li
Journal:  Dis Markers       Date:  2022-07-08       Impact factor: 3.464

4.  Identification of TLR2 Signalling Mechanisms Which Contribute to Barrett's and Oesophageal Adenocarcinoma Disease Progression.

Authors:  Ewelina Flis; Gillian Barber; Ciara Nulty; Brian Keogh; Peter McGuirk; Akanksha Anand; Jacintha O'Sullivan; Michael Quante; Emma M Creagh
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

5.  Cell pyroptosis in health and inflammatory diseases.

Authors:  Yongqi Wu; Jing Zhang; Sihui Yu; Yan Li; Jinrong Zhu; Kai Zhang; Rongxin Zhang
Journal:  Cell Death Discov       Date:  2022-04-11

Review 6.  Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment.

Authors:  Xiaoxia Huang; Yao Wang; Wenhui Yang; Jing Dong; Lin Li
Journal:  Front Nutr       Date:  2022-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.